BR112013008695A2 - compostos de 7-hidróxi-pirazol[1,5-a] pirimidina e seu uso como antagonistas do receptor ccr2 - Google Patents

compostos de 7-hidróxi-pirazol[1,5-a] pirimidina e seu uso como antagonistas do receptor ccr2

Info

Publication number: BR112013008695A2
Authority: BR; Brazil
Prior art keywords: pyrazolo; hydroxy; receptor antagonists; pyrimidine compounds; ccr2 receptor
Prior art date: 2010-09-27

Application number

BR112013008695A

Other languages

English (en)

Inventor

David Mountford

Edward Daniel Savory

Iain Simpson

Joe William Boyd

Michael Higginbottom

Paul Meo

Original Assignee

Proximagen Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-09-27

Filing date

2011-09-26

Publication date

2016-06-21

2010-09-27 Priority claimed from GBGB1016221.2A external-priority patent/GB201016221D0/en

2011-08-15 Priority claimed from GBGB1113971.4A external-priority patent/GB201113971D0/en

2011-09-26 Application filed by Proximagen Ltd filed Critical Proximagen Ltd

2016-06-21 Publication of BR112013008695A2 publication Critical patent/BR112013008695A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Immunology (AREA)
Diabetes (AREA)
Oncology (AREA)
Hematology (AREA)
Dermatology (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Neurology (AREA)
Ophthalmology & Optometry (AREA)
Transplantation (AREA)
Otolaryngology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

BR112013008695A 2010-09-27 2011-09-26 compostos de 7-hidróxi-pirazol[1,5-a] pirimidina e seu uso como antagonistas do receptor ccr2 BR112013008695A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB1016221.2A GB201016221D0 (en)	2010-09-27	2010-09-27	New compounds
GBGB1113971.4A GB201113971D0 (en)	2011-08-15	2011-08-15	New compounds ii
PCT/EP2011/066697 WO2012041817A1 (en)	2010-09-27	2011-09-26	7-hydroxy-pyrazolo[1,5-a] pyrimidine compounds and their use as ccr2 receptor antagonists

Publications (1)

Publication Number	Publication Date
BR112013008695A2 true BR112013008695A2 (pt)	2016-06-21

Family

ID=45891994

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR112013008695A BR112013008695A2 (pt)	2010-09-27	2011-09-26	compostos de 7-hidróxi-pirazol[1,5-a] pirimidina e seu uso como antagonistas do receptor ccr2

Country Status (10)

Country	Link
US (1)	US20130252951A1 (pt)
EP (1)	EP2621928A1 (pt)
JP (1)	JP2013538838A (pt)
CN (1)	CN103328479A (pt)
AU (1)	AU2011310713A1 (pt)
BR (1)	BR112013008695A2 (pt)
CA (1)	CA2811934A1 (pt)
IL (1)	IL225299A0 (pt)
SG (1)	SG189086A1 (pt)
WO (1)	WO2012041817A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN105980386B (zh) *	2013-03-13	2021-08-13	基因泰克公司	吡唑并化合物及其用途
UY35735A (es)	2013-09-16	2015-04-30	Bayer Pharma AG	Trifluorometilpirimidinonas disustituidas y su uso
WO2016104777A1 (ja) *	2014-12-26	2016-06-30	国立大学法人九州大学	がんの処置のための方法
WO2016113205A1 (de)	2015-01-13	2016-07-21	Bayer Pharma Aktiengesellschaft	Substituierte pentafluorethylpyrimidinone und ihre verwendung
BR112019010375A2 (pt) *	2016-11-23	2019-08-27	Chemocentryx Inc	método de tratamento de glomeruloesclerose segmental focal
PE20210340A1 (es)	2017-09-15	2021-02-22	Aduro Biotech Inc	Compuestos que contienen pirazolopirimidinona y sus usos
SG11202002975YA (en) *	2017-10-11	2020-04-29	Chemocentryx Inc	Treatment of focal segmental glomerulosclerosis with ccr2 antagonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3338292A1 (de) *	1983-10-21	1985-05-02	Basf Ag, 6700 Ludwigshafen	7-amino-azolo(1,5-a)-pyrimidine und diese enthaltende fungizide
EP0503099A4 (en)	1990-10-09	1993-12-01	Otsuka Pharmaceutical Co., Ltd.	Pyrimidine derivative, production thereof, and androgen inhibitor
FR2687676B1 (fr) *	1992-02-24	1994-07-08	Union Pharma Scient Appl	Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii; leurs procedes de preparation, compositions pharmaceutiques les contenant.
FR2687677B1 (fr)	1992-02-24	1996-10-11	Union Pharma Scient Appl	Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant.
EP0984692A4 (en)	1997-05-30	2001-02-21	Merck & Co Inc	ANGIOGENESIS INHIBITORS
WO2004052286A2 (en)	2002-12-11	2004-06-24	Merck & Co., Inc.	Tyrosine kinase inhibitors
US20100075993A1 (en) *	2005-06-30	2010-03-25	Drexel University	Small molecule inhibitors against west nile virus replication
WO2008116898A1 (en) *	2007-03-28	2008-10-02	Biovitrum Ab (Publ)	Pyrazolo [1,5-a]pyrimidines as inhibitors of stearoyl-coa desaturase
CA2709784A1 (en) *	2007-12-21	2009-07-09	University Of Rochester	Method for altering the lifespan of eukaryotic organisms
WO2009106539A1 (en) *	2008-02-26	2009-09-03	Novartis Ag	Heterocyclic compounds as inhibitors of cxcr2
WO2011114148A1 (en) *	2010-03-17	2011-09-22	Astrazeneca Ab	4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
WO2011135491A1 (en) *	2010-04-26	2011-11-03	Basf Se	Herbicidal azolopyrimidines
WO2011140333A1 (en) *	2010-05-07	2011-11-10	The Board Of Trustees Of The Leland Stanford Junior University	Identification of stabilizers of multimeric proteins

2011
- 2011-09-26 JP JP2013530694A patent/JP2013538838A/ja not_active Ceased
- 2011-09-26 WO PCT/EP2011/066697 patent/WO2012041817A1/en active Application Filing
- 2011-09-26 EP EP11763912.0A patent/EP2621928A1/en not_active Withdrawn
- 2011-09-26 SG SG2013022108A patent/SG189086A1/en unknown
- 2011-09-26 BR BR112013008695A patent/BR112013008695A2/pt not_active IP Right Cessation
- 2011-09-26 CA CA2811934A patent/CA2811934A1/en not_active Abandoned
- 2011-09-26 CN CN2011800523704A patent/CN103328479A/zh active Pending
- 2011-09-26 US US13/876,220 patent/US20130252951A1/en not_active Abandoned
- 2011-09-26 AU AU2011310713A patent/AU2011310713A1/en not_active Abandoned
2013
- 2013-03-18 IL IL225299A patent/IL225299A0/en unknown

Also Published As

Publication number	Publication date
JP2013538838A (ja)	2013-10-17
WO2012041817A1 (en)	2012-04-05
SG189086A1 (en)	2013-05-31
AU2011310713A1 (en)	2013-04-11
IL225299A0 (en)	2013-06-27
CN103328479A (zh)	2013-09-25
EP2621928A1 (en)	2013-08-07
US20130252951A1 (en)	2013-09-26
CA2811934A1 (en)	2012-04-05

Publication	Publication Date	Title
BR112012029437A2 (pt)	2017-03-07	derivados de pirrolo[2,3-b]pirazina-7-carboxamida e seu uso como inibidores de jak e syk
HRP20190361T1 (hr)	2019-04-05	Derivati triazolo[4,5-d]pirimidina kao antagonisti cb2 receptora
BRPI0813831A2 (pt)	2015-01-06	Compostos de heteroarila bicíclica e seu uso como inibidores de quinase
BRPI0919844A2 (pt)	2019-09-24	compostos de azaindazol como antagonistas do receptor ccr1
BR112013016030A2 (pt)	2018-07-24	compostos e seu uso como inibidores de bace
BRPI1015145A2 (pt)	2018-01-30	derivados de tiazol e seu uso como receptores antagonistas de p2y12
BR112013011520A2 (pt)	2019-09-24	pirazolo piridinas e pirazolo piridinas e seu uso como inibidores de tyk2
BRPI0920448A2 (pt)	2018-10-23	compostos spiro-oxindol e seu uso como agentes terapêuticos
BRPI0821141A2 (pt)	2015-06-16	Derivados de heteroarila como antagonistas do receptor de orexina
SMT201600155B (it)	2016-07-01	Pirazolo[i, 5-a]pirimidine e -triazine come agenti antivirali
BRPI0909157A2 (pt)	2015-11-24	compostos heterocíclicos como antagonistas de receptores de adenosina
BR112013008695A2 (pt)	2016-06-21	compostos de 7-hidróxi-pirazol[1,5-a] pirimidina e seu uso como antagonistas do receptor ccr2
CR10249A (es)	2008-11-26	Compuestos de amino- pirimidina 2,6-sistituidos -4-monosustituidos como antagonistas del receptor de prostaglandina d2
BRPI0908225A2 (pt)	2016-11-01	derivados de piridazina e seu uso como agentes terapêuticos
BRPI0817245A2 (pt)	2015-06-16	Derivados e quinolina como antagonistas receptores de 5ht5a
BRPI0720866A2 (pt)	2014-03-04	Derivados de oxindol substituídos e seu uso como ligandos de receptor de vasopressina
BRPI0717937A2 (pt)	2013-12-03	Compostos de pirazona como antagonistas do receptor mineralocorticóide
BRPI0913885A2 (pt)	2015-08-25	Tiadiazoliloxifenilamidinas e seus uso como fungicidas
BRPI1008850A2 (pt)	2016-03-15	[1,2,4]triazolo[1,5-a]piridinas como inibidores de quinase
BRPI0817061A2 (pt)	2015-03-24	Derivados de pirrolidinilalquilisoquinolinona e -isoindolinona como antagonistas de histamina-3
CO6930360A2 (es)	2014-04-28	Derivados de [1,2,3]triazolo[4,5-d]pirimidina como agonistas preferentes del receptor de canabinoides 2
BRPI0922303A2 (pt)	2016-01-12	arilciclo-hexiléteres de di-hidrotetra-azabenzoazulenos para o uso como antagonistas do receptor de vasopressina v1a
CO6781555A2 (es)	2013-10-31	Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación
BRPI0921669A2 (pt)	2018-06-26	piperazina de arila e seu uso como antagonistas alfa 2c
BRPI0915834A2 (pt)	2015-11-03	6-(1-piperazinil)-piridazinas substituídas como antagonistas do receptor de 5-ht6

Legal Events

Date	Code	Title	Description
2016-09-20	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 5A ANUIDADE.
2017-01-10	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.